Prime Medicine, Inc. - Common Stock — Quarterly Cash Flow (NASDAQ:PRME) | MetaTrader

Open full chart

Financials

Overview Statement Statistics Dividends

Quarterly Annual

Total assets 328.16 M279.01 M385.01 M342.73 M294.73 M Total liabilities 221.24 M218.15 M223.19 M221.87 M218.03 M Total equity 106.92 M60.86 M161.82 M120.87 M76.7 M Total liabilities & shareholders' equities 328.16 M279.01 M385.01 M342.73 M294.73 M Total debt ————— Net debt —————

News

Prime Medicine Beats Beam Therapeutics In Patent Dispute - But Both Are Investable (PRME)

Gene Editors, Including Powerhouse Beam Therapeutics, Diverge On Legal Battle

Foghorn Therapeutics (FHTX) Surges 5.8%: Is This an Indication of Further Gains?

Beam Therapeutics: A Better Entry Point Is Likely Coming (Rating Downgrade) (NASDAQ:BEAM)

Prime Medicine's Prime Editing Is Worth The Risk (NASDAQ:PRME)

Prime Medicine, Inc. (PRME) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Prepared Remarks Transcript

Prime Medicine, Inc. (PRME) Presents at Jefferies Global Healthcare Conference 2026 Transcript

Prime Medicine, Inc. (PRME) Reports Q1 Loss, Misses Revenue Estimates

RenovoRx, Inc. (RNXT) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Harmony Biosciences Holdings, Inc. (HRMY) Q1 Earnings and Revenues Miss Estimates

Prime Medicine, Inc. (PRME) Presents at TD Cowen 46th Annual Health Care Conference Transcript

Citizens reiterates Prime Medicine stock rating on PM359 pathway